Rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism, with a hazard ratio of 0.79 (95% CI, 0.66 to 0.96).
RCT
Central computerized randomization
Double-blind
Yes
Does rivaroxaban prevent stroke or systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
Patients with nonvalvular atrial fibrillation
Rivaroxaban
Warfarin
Stroke or systemic embolismhard clinical
Rivaroxaban is a noninferior alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation, offering a lower risk of intracranial and fatal bleeding.
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson ROCKET AF ClinicalTrials.gov number, NCT00403767.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Manesh R. Patel
Kenneth W. Mahaffey
Jyotsna Garg
New England Journal of Medicine
Harvard University
Massachusetts General Hospital
Duke University
Building similarity graph...
Analyzing shared references across papers
Loading...
Patel et al. (Wed,) conducted a rct in Nonvalvular atrial fibrillation (n=14,264). Rivaroxaban vs. Warfarin (dose-adjusted) was evaluated on Composite of stroke (ischemic or hemorrhagic) and systemic embolism (HR 0.79, 95% CI 0.66-0.96, p=<0.001). Rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism, with a hazard ratio of 0.79 (95% CI, 0.66 to 0.96).
www.synapsesocial.com/papers/69813150ce4d1f8e18d4e860 — DOI: https://doi.org/10.1056/nejmoa1009638